Blood-based biomarkers in Alzheimer disease

Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

Biofluid Based Biomarker Professional Interest Area

Research output: Contribution to journalShort surveyResearchpeer-review

63 Citations (Scopus)

Abstract

The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

Original languageEnglish
Pages (from-to)45-58
Number of pages14
JournalAlzheimer's and Dementia
Volume13
Issue number1
DOIs
StatePublished - 1 Jan 2017

Fingerprint

Alzheimer Disease
Biomarkers
Public-Private Sector Partnerships
Research
Neurodegenerative Diseases
Industry
Costs and Cost Analysis

Keywords

  • Alzheimer's disease
  • Biomarker
  • Blood
  • Cerebrospinal fluid
  • Context of use
  • Diagnosis
  • Diagnosis
  • Imaging

Cite this

@article{9549a1e60d394b8c932ac382a3f1640e,
title = "Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic",
abstract = "The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.",
keywords = "Alzheimer's disease, Biomarker, Blood, Cerebrospinal fluid, Context of use, Diagnosis, Diagnosis, Imaging",
author = "{Biofluid Based Biomarker Professional Interest Area} and O'Bryant, {Sid E.} and Mielke, {Michelle M.} and Sidney O'Bryant and Simone Lista and Hugo Vanderstichele and Henrik Zetterberg and Piotr Lewczuk and Holly Posner and James Hall and Leigh Johnson and James Hall and Johnson, {Leigh A.} and Andreas Jeromin and Richard Batrla-Utermann and Alcibiades Villarreal and Gabrielle Britton and Snyder, {Peter J.} and Kim Henriksen and Paula Grammas and Veer Gupta and Ralph Martins and Harald Hampel",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.jalz.2016.09.014",
language = "English",
volume = "13",
pages = "45--58",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",

}

Blood-based biomarkers in Alzheimer disease : Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. / Biofluid Based Biomarker Professional Interest Area.

In: Alzheimer's and Dementia, Vol. 13, No. 1, 01.01.2017, p. 45-58.

Research output: Contribution to journalShort surveyResearchpeer-review

TY - JOUR

T1 - Blood-based biomarkers in Alzheimer disease

T2 - Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

AU - Biofluid Based Biomarker Professional Interest Area

AU - O'Bryant, Sid E.

AU - Mielke, Michelle M.

AU - O'Bryant, Sidney

AU - Lista, Simone

AU - Vanderstichele, Hugo

AU - Zetterberg, Henrik

AU - Lewczuk, Piotr

AU - Posner, Holly

AU - Hall, James

AU - Johnson, Leigh

AU - Hall, James

AU - Johnson, Leigh A.

AU - Jeromin, Andreas

AU - Batrla-Utermann, Richard

AU - Villarreal, Alcibiades

AU - Britton, Gabrielle

AU - Snyder, Peter J.

AU - Henriksen, Kim

AU - Grammas, Paula

AU - Gupta, Veer

AU - Martins, Ralph

AU - Hampel, Harald

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

AB - The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

KW - Alzheimer's disease

KW - Biomarker

KW - Blood

KW - Cerebrospinal fluid

KW - Context of use

KW - Diagnosis

KW - Diagnosis

KW - Imaging

UR - http://www.scopus.com/inward/record.url?scp=85009063579&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.09.014

DO - 10.1016/j.jalz.2016.09.014

M3 - Short survey

VL - 13

SP - 45

EP - 58

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 1

ER -